M1FG
BBIO icon

Mach-1 Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Mach-1 Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,476
Closed -$409K – 265
2025
Q2 		$409K Buy
+9,476
New +$345K 0.12% 141

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mach-1 Financial Group's BBIO Position: Q3 2025 in Review

Mach-1 Financial Group sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 9,476 shares — an estimated $409K sold.

Mach-1 Financial Group first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $409K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Mach-1 Financial Group reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 9,476 BridgeBio Pharma shares in Q3 2025, an estimated $409K.
  • Mach-1 Financial Group first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's BridgeBio Pharma position peaked at $409K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.